Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Dirk Schadendorf, О. В. Леонов et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 146
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trialPaul Nathan, Dirk Schadendorf, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 68
Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplificationJan C. Brase, Ulrike Korf|Proteome Science|2010Cited by 19
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.Reinhard Dummer, Georgina V. Long, Axel Hauschild et al.|Journal of Clinical Oncology|2018Cited by 1